

NCT ID	NCT05999812
Title	Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer
Phase	Phase 2
Date Added	2023-08-21
Location	Texas, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	all trans Retinoic Acid, Atezolizumab, Bevacizumab
Tags	MSS/ MMRp
NCT ID	NCT06006923
Title	Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer
Phase	Phase 2
Date Added	2023-08-23
Location	California, United States Florida, United States Illinois, United States Pennsylvania, United States Washington, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Pembrolizumab, Regorafenib, Keytruda, Stivarga
Tags	MSI-H/ MMRd
NCT ID	NCT06014502
Title	Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
Phase	Phase 1
Date Added	2023-08-28
Location	Louisiana, United States Texas, United States
Prior IO Allowed	No
CRC-directed	No
Status	Recruiting
Drugs	IMGS-001
Tags	MSI-H/ MMRd
NCT ID	NCT06176885
Title	Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer
Phase	Phase 2
Date Added	2023-12-20
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Camrelizumab
Tags	MSS/ MMRp
NCT ID	NCT06106308

Title	Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
Phase	Phase 2
Date Added	2023-10-30
Location	Arizona, United States Arkansas, United States California, United States Florida, United States Hawaii, United States Indiana, United States Kansas, United States Michigan, United States Minnesota, United States Missouri, United States Nevada, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Wisconsin, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Bevacizumab, FOLFIRI, FOLFOX, Onvansertib
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT06107413
Title	Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
Phase	Phase 2
Date Added	2023-10-30
Location	Arizona, United States Arkansas, United States California, United States Connecticut, United States Florida, United States Illinois, United States Indiana, United States Louisiana, United States Minnesota, United States North Carolina, United States South Carolina, United States South Dakota, United States Texas, United States Virginia, United States Belgium Germany Israel Japan Korea, Republic of Spain Taiwan
Prior IO Allowed	No
CRC-directed	Yes

Status	Recruiting
Drugs	ABBV-400, Bevacizumab, fluorouracil, Folinic acid, Irinotecan
Tags	MSS/ MMRp
NCT ID	NCT05286814
Title	M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma
Phase	Phase 2
Date Added	2022-03-18
Location	Maryland, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSS/ MMRp
NCT ID	NCT04041310
Title	Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
Phase	Phase 1, Phase 2
Date Added	2019-08-01
Location	California, United States Florida, United States Indiana, United States Maryland, United States Missouri, United States New York, United States Texas, United States Belgium Canada Italy Spain United Kingdom
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	
Tags	MSI-H/ MMRd
NCT ID	NCT05865535
Title	A Dose Escalation Study of AV-380 in Metastatic Cancer Patients With Cachexia
Phase	Phase 1
Date Added	2023-05-19
Location	California, United States Florida, United States Georgia, United States Nebraska, United States New York, United States Oregon, United States South Carolina, United States Tennessee, United States Texas, United States
Prior IO Allowed	No
CRC-directed	No
Status	Recruiting
Drugs	

